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Abstract
Background:  The Nonsense-Mediated mRNA Decay (NMD) pathway detects and degrades
mRNAs containing premature termination codons, thereby preventing the accumulation of
potentially detrimental truncated proteins. Intertissue variation in the efficiency of this mechanism
has been suggested, which could have important implications for the understanding of genotype-
phenotype correlations in various genetic disorders. However, compelling evidence in favour of
this hypothesis is lacking. Here, we have explored this question by measuring the ratio of mutant
versus wild-type Men1 transcripts in thirteen tissues from mice carrying a heterozygous truncating
mutation in the ubiquitously expressed Men1 gene.
Results: Significant differences were found between two groups of tissues. The first group, which
includes testis, ovary, brain and heart, displays a strong decrease of the nonsense transcript
(average ratio of 18% of mutant versus wild-type Men1 transcripts, identical to the value measured
in murine embryonic fibroblasts). The second group, comprising lung, intestine and thymus, shows
much less pronounced NMD (average ratio of 35%). Importantly, the extent of degradation by
NMD does not correlate with the expression level of eleven genes encoding proteins involved in
NMD or with the expression level of the Men1 gene.
Conclusion: Mouse models are an attractive option to evaluate the efficiency of NMD in multiple
mammalian tissues and organs, given that it is much easier to obtain these from a mouse than from
a single individual carrying a germline truncating mutation. In this study, we have uncovered in the
thirteen different murine tissues that we examined up to a two-fold difference in NMD efficiency.
Background
Messenger RNA (mRNA) quality control is essential to
assure the fidelity of gene expression. It is achieved
through several mechanisms among which Nonsense-
Mediated mRNA Decay (NMD) plays a major role. The
NMD pathway detects and degrades mRNAs containing
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premature termination codons (PTCs), thereby prevent-
ing the accumulation of potentially harmful truncated
proteins [1]. NMD is evolutionary conserved, although
the way PTCs are recognized by the surveillance machin-
ery may differ between species. In mammals, PTC recog-
nition depends upon the position of the stop codon
within the transcript. The normal stop codon is nearly
always located in the last exon [2], so any stop codon
located >50 nucleotides upstream of the last exon-exon
boundary will be considered as premature. Recognition is
thought to occur during a pioneering round of transla-
tion, and exon-exon boundaries are delimited on the tran-
script by exon-exon junction complexes (EJCs) deposited
during splicing [3].
The NMD pathway has important repercussions on the
manifestation of human genetic diseases. Although trun-
cating mutations, i.e. mutations that introduce a PTC in
the coding sequence, are usually not expected to lead to
substantial amounts of truncated proteins, there are situa-
tions where the mutant transcripts escape NMD. This hap-
pens when the PTC is located in the last exon [4,5], at the
beginning of the coding sequence where it can possibly
induce translation reinitiation [6-8], or when the PTC is
absent from the mutant transcript because of exon skip-
ping [4,9]. Differences in the ability of PTC-containing
mRNAs to trigger NMD have been found to explain sev-
eral phenotype/genotype correlations [10,11]. The most
striking examples are β-thalassemia (MIM 141900),
which is commonly a recessive disorder, but shows a
dominant inheritance pattern when mutations in the β-
globin gene are NMD-incompetent [12], and two different
peripheral neuropathies that are both the result of truncat-
ing mutations in the SOX10 gene that differ in their ability
to trigger NMD [13].
NMD has also long been suspected to influence the clini-
cal outcome of genetic diseases as a result of intertissue
variation in the efficiency of this mechanism. Variation in
NMD efficiency could lead to the expression of variable
amounts of truncated proteins depending on the tissue
considered, which might in turn help to explain why trun-
cating mutations in ubiquitously or widely expressed
genes appear to affect only a very specific and small subset
of tissues in humans. Evidence for variation of NMD effi-
ciency comes from the observation that in patients carry-
ing PTCs in the collagen X gene, low abundance of mutant
transcripts was observed in cartilage cells due to NMD,
while in lymphoblasts and bone cells, no NMD-mediated
mRNA diminution was observed [14].
Here, we have explored the question of variation in NMD
efficiency by measuring the relative amount of a PTC-con-
taining  Men1  transcript, as compared to the transcript
level of the wild-type allele, in 13 tissues taken from het-
erozygous Men1 knockout mice. We observed that there is
up to a two-fold difference in the efficiency of NMD
between the examined tissues.
Results
NMD degradation of mutant Men1 transcripts in Men1+/Δ 
mice model
The murine Men1 gene, like its human ortholog, contains
10 exons, of which nine are coding. It has been described
that four different Men1 transcripts displaying the same
coding sequence are produced through alternative splic-
ing of intron 1 [15,16]. The mouse model we have used in
this analysis has been generated by deleting exon 3 in one
allele of Men1  [17]. This deletion introduces a PTC in
exon 4 of the coding sequence, 164 ter (Figure 1a). Heter-
ozygous  Men1  knockout (Men1+/Δ) mice of both sexes
develop normally and are fertile and healthy until they are
at least 7 months of age [17]. Men1+/Δ mouse embryonic
fibroblasts (MEF) were used to verify that PTC-containing
Men1  transcripts were subjected to NMD as expected,
given the presence of six exon-exon junctions downstream
of the PTC. We found by real time quantitative RT-PCR
that mutant transcripts were present at levels of 18% and
60% of their wild-type counterpart without and with the
NMD inhibitor puromycin, respectively (Figure 1b).
Relative amount of Men1 mutant transcripts
We measured the ratio of mutant versus wild-type Men1
transcripts in 13 different tissues taken from four Men1+/Δ
mice. The values ranged from 16% to 36%, as seen on Fig-
ure 2. Statistical analysis showed that there was a signifi-
cant difference between two distinct groups of tissues; one
comprised of testis/ovarian, brain and heart (average ratio
of 18%), and the other of lung, intestine and thymus
(average ratio of 35%).
The Men1 gene has been reported to be expressed in all the
tissues examined, albeit at variable levels, by Northern
blot analysis [16,18,19]. Quantification by quantitative
RT-PCR analysis confirmed this finding. The number of
copies was normalized to the amount of Hprt1 and β-actin
transcripts (Figure 3). The lowest level of Men1 transcripts
was found in spleen and stomach while the highest level
was found in testis and brain (nearly 4-fold difference);
the differences observed in the other tissues were not sta-
tistically significant. No correlation between NMD effi-
ciency and Men1 transcript levels was observed.
Expression levels of the genes involved in NMD
NMD triggering in humans, based on present models,
hinges on the interaction of critical protein components,
hUpf2, hUpf3a/hUpf3b, that are bound to the EJC (com-
posed in the cytoplasm of Y14, Magoh, eIF4AIII and hBar-
entsz) with a molecule, hUpf1, recruited to the post-
termination complex deposited at the PTC [3]. The SMG1BMC Genetics 2008, 9:83 http://www.biomedcentral.com/1471-2156/9/83
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kinase, in turn, binds to this complex and phosphorylates
hUpf1, which leads to subsequent recruitment of RNA
degrading enzymes. The association of these proteins with
the post-spliced mRNA is essential as their depletion,
mediated by RNA interference, has been shown to sup-
press degradation of NMD substrates [20,21]. Further-
more, NMD can be recapitulated by tethering the hUpf
factors, Magoh, Y14, eIF4AIII, or hBarentsz within the
3'UTR of a reporter mRNA in human cells [22].
Human  UPF1  [23],  UPF2  [24],  MAGOH  [25],  CASC3
(encoding hBarentsz) [26], and EIF4A3 [27] genes have
been shown to be ubiquitously expressed by Northern
blot, but their level of expression varies among tissues. In
order to more precisely determine the extent of these var-
iations in mice, and to investigate the possibility of an
eventual link with NMD efficiency, we have measured the
amount of mRNAs transcribed from the genes encoding
nine of the proteins involved in NMD by real time quan-
Description of the Men1 mouse model used in the analysis Figure 1
Description of the Men1 mouse model used in the analysis. (a) Schematic representation of the mutant and of the wild-
type allele of the Men1 gene in the heterozygous Men1 mutant mice. Black boxes and lines represent exons and introns respec-
tively. The grey horizontal arrow depicts a loxP sequence, and the black vertical arrow shows the location of the premature 
stop codon generated by exon 3 deletion. The strategy used to delete Men1 exon 3 in mice has been described previously [17]. 
(b) Transcript copy number were measured by quantitative RT-PCR using 50 pg of RNA extracted from Men1+/Δ mouse 
embryonic fibroblasts (MEF) untreated or treated with puromycin (Puro). Specific amplification of either the wild-type (WT) or 
the mutant (Mu) transcript lacking exon 3 was achieved using the primers described in the Methods section.
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titative RT-PCR: Upf1,  Upf2,  Upf3a,  Upf3b,  Smg1  (also
known as RICKEN), y14 (also known as Rbm8a), Mago,
Casc3 and Eif4a3 (Figure 4 and 5). We also analysed the
level of expression of the genes encoding the splicing
coactivators/alternative splicing factors that have been
shown to interact with the EJC, SRm160 and RNPS1
(Srrm1 and Rnps1 respectively in mice) (Figure 6), given
the described link between efficiency of splicing and effi-
ciency of NMD [28], and given the fact that the abundance
of RNPS1 has been reported to determine the variability
in efficiency of NMD in three strains of HeLa cells [29].
The same RNA samples were used as previously described
for measuring levels of Men1 transcripts, and the number
of copies was likewise normalized to the amount of Hprt1
and β-actin transcripts. A great variation in the mean level
of expression of the eleven studied genes was observed:
Mago transcripts (1000 copy per 50 pg of total RNA) are
500 times more abundant than Casc3 transcripts (2 cop-
ies). Included within these boundaries are Rnps1 (275
copies), y14 (265 copies), Upf3a (160 copies), Srrm1 (130
copies), Eif4a3 (100 copies), Upf3b (90 copies), Upf2 (60
copies), Upf1 (15 copies) and Smg1 (10 copies).
Concerning tissues variations, no statistical difference in
the amount of transcripts was seen in the case of Rnps1
(Figure 6). For y14, testis and heart were significantly dif-
ferent from ovary, brain, stomach, adrenal, spleen, mam-
mary gland, kidney and intestine (Figure 5). Testis, heart
and thymus were significantly different from brain, intes-
tine, mammary gland, spleen and stomach for Mago (Fig-
ure 5). For the remaining genes, the only tissue showing a
significant variation was testis (Figure 4, 5, 6), with an
amount of transcripts 4 to 50 times higher than in all the
other tissues. No clear correlation could be drawn
between the efficiency of NMD and the level of expression
of any of the mRNAs encoding proteins essential to this
mechanism.
Discussion
Intertissue variation in NMD efficiency has long been sug-
gested to modulate the clinical outcome of genetic dis-
eases. Indeed, such a variation would mean that in some
tissues more than in others, translation of residual
mRNAs containing PTCs could potentially lead to func-
NMD efficiency in 13 tissues of mice heterozygous for a truncating mutation in the Men1 gene Figure 2
NMD efficiency in 13 tissues of mice heterozygous for a truncating mutation in the Men1 gene. NMD efficiency is 
expressed as a ratio of the amount of mutant Men1 transcripts versus wild-type species, as measured by quantitative RT-PCR. 
Each bar on the graph represents the mean value of at least 3 independent measurements (± standard deviation) in four sam-
ples of the same tissue (two samples only were used for testis and ovary).
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tionally important expression of truncated proteins and
influence the phenotype.
The first hint that NMD efficiency could vary between tis-
sues from the same individual came from the study by
Bateman and colleagues on truncating mutations in the
collagen X gene, COL10A1, responsible for Schmid meta-
physeal chondrodysplasia (MIM 156500) [14]. They
showed that NMD completely removed the mutant
COL10A1 transcripts in cartilage tissue and cells, but not
in non-cartilage cells. However, this COL10A1 study pre-
sented two particularities that could restrict the notion of
NMD efficiency variation to this gene. Firstly, nonsense-
mediated reduction in abundance of nonsense COL10A1
mRNAs is not governed by the same parameters as those
in the classical process. Indeed, competency for NMD in
this case is specified by the 3'UTR and mRNA decay is only
triggered by truncating mutations introducing a PTC in a
3' region of the terminal exon, which contain more than
90% of the coding sequence [30]. Secondly, the COL10A1
gene is expressed exclusively in cartilage cells, and there-
fore, NMD of COL10A1  PTC-containing transcripts in
non-cartilage cells (bone cells and lymphoblasts) was
assessed on "illegitimate" transcripts, i.e. tissue-specific
transcripts found at very low levels in non-expressing
cells. A correlation between the amount of transcripts and
the extent of degradation by NMD was not observed in the
case of the Men1 gene in our study. However, Men1 is
ubiquitously expressed and variations of a maximum 5-
fold were observed amongst the studied tissues. It remains
possible that illegitimate COL10A1  transcripts are not
translated and that this is the reason why they are not sub-
jected to NMD.
Another related, but distinct matter, concerns interindi-
vidual variation in NMD efficiency. Patients carrying iden-
tical mutations can show variable reduction of mutant
transcript levels in the same cell type [4,31]. In the study
of Linde and coll., interindividual variability in NMD effi-
ciency was not only observed in the case of the CFTR tran-
scripts in nasal epithelial cells from patients carrying the
W1282X mutation but also in the case of five natural
NMD substrates in epithelial cell lines derived from two
unrelated patients carrying the same mutations [31].
While intertissue variations of NMD efficiency are proba-
bly the result of differences between tissues in the level of
expression of the proteins involved in NMD, interindivid-
ual variations are likely to be linked to DNA variations in
Men1 transcript levels in 13 murine tissues Figure 3
Men1 transcript levels in 13 murine tissues. Transcript levels (copy number per 50 pg of RNA extracted from each of the 
mentioned tissue) were measured by quantitative RT-PCR, and normalized to the level of Hprt1 and β-actin transcripts. Each 
bar on the graph represents the mean value of 3 independent measurements (± standard deviation) in four samples of the same 
tissue (two samples only were used for testis and ovary).
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the human genome within the genes encoding the pro-
teins involved in NMD. These two levels of variations are
intermingled when the efficiency by which the same trun-
cating mutation triggers NMD is compared in different tis-
sues of different individuals, as in the study by Resta et al
[32], and it is therefore not possible in these situations to
estimate the contribution of each phenomenon.
Given the difficulties to obtain different tissues from a sin-
gle patient, mouse models appeared as an attractive alter-
native to evaluate the efficiency of NMD in multiple
mammalian tissues. Indeed, this question was addressed
in a study using the gusmps mouse, a model of mucopoly-
saccharidosis type VII (MIM 253220), which harbours a
NMD-competent truncating mutation in the ubiquitously
expressed  β-glucuronidase gene [24]. However, only
homozygous animals were studied, which precluded
measurement of steady-state levels of mutant versus wild-
type transcripts in different tissues of the same mouse.
Their analysis, performed by Northern blot, reported that
all eight tissues examined (thymus, spleen, skeletal mus-
cle, liver, kidney, lung, heart and brain) showed efficient
degradation of the mutant transcript as it was undetecta-
ble in Gus null mutant mice [24], but was not able to
Transcript levels of the Upf1-3 and Smg1 genes in 13 murine tissues Figure 4
Transcript levels of the Upf1-3 and Smg1 genes in 13 murine tissues. Transcript levels (copy number per 50 pg of 
RNA extracted from each of the mentioned tissues) were measured by quantitative RT-PCR using the same samples as previ-
ously, and normalized to the level of Hprt1 and β-actin transcripts. Each bar on the graph represents the mean value of at least 
3 independent measurements (± standard deviation) in four samples of the same tissue (two samples only were used for testis 
and ovary). Please note that the scale showing the normalized number of transcripts is different for each gene. Ov: ovary; Te: 
testis; Br: brain; He; heart; St; stomach; Ad: adrenal gland; Li: liver; Sp: spleen; M.G.: mammary gland; Ki: kidney; Lu: lung; In: 
intestine; Th: thymus.
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uncover discrete variations in NMD efficiency. A recent
study performed on a knockin mouse model in which one
wild-type Chek2 allele has been replaced by an allele car-
rying the 1100delC mutation showed that the mutant
transcripts undergo NMD in MEFs and in four tissues
(brain, heart, kidney and liver), but to varying degrees
[33]. This analysis was performed by quantitative RT-PCR
on RNA extracted from tissues taken from wild-type,
Chek2  1100delC heterozygous and Chek2  1100delC
homozygous animals. The RT-PCR protocol used did not
allow the discrimination between the wt and the mutant
Chek2  transcript species and therefore, NMD efficiency
Transcript levels of the genes encoding the EJC core proteins in 13 murine tissues Figure 5
Transcript levels of the genes encoding the EJC core proteins in 13 murine tissues. Transcript levels (copy number 
per 50 pg of RNA extracted from each of the mentioned tissues) were measured by quantitative RT-PCR using the same sam-
ples as previously, and normalized to the level of Hprt1 and β-actin transcripts, as in Figure 4.
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was expressed as the amount of both transcripts normal-
ized to GAPDH transcripts. Variations were observed, but
it couldn't be ruled out that they result from variations in
the levels of the GAPDH transcripts, as these have been
reported to vary depending on the tissues examined [34].
Here, we have quantified for the first time the extent of
variation in NMD efficiency by measuring the ratio of
mutant versus wild-type Men1  transcripts in 13 tissues
taken from mice heterozygous for a truncating mutation,
and have found up to a two-fold difference. The organs
most frequently involved clinically in the Men1 syndrome
(the parathyroids, the pituitary and the pancreas) were
not all tested in our analysis; furthermore, it has not been
possible to verify the expression of a truncated menin pro-
tein as all the available antibodies are directed against the
C-terminal part of the Menin protein. Therefore, we have
not been able to assess whether the differences in NMD
efficiency that we have uncovered plays a role in the phys-
iopathology of the disease in the Men1+/Δ mice.
Although NMD efficiency varies depending upon the
gene, we do not expect that the extent of variation that we
have observed is specific to the Men1 gene. However, our
results need to be confirmed with other mouse models
carrying a heterozygous truncating mutation in ubiqui-
tously-expressed genes. Additionally, it would be interest-
ing to also test physiologic NMD substrates.
Unfortunately, several features shared by these physio-
logic substrates limit their use to disclose intertissue vari-
ations of NMD efficiency. Indeed, the examination of the
expression profile in human cells depleted of hUpf1
revealed that most upregulated transcripts result from
alternative splicing events or from the use of alternative
translation start site that introduce upstream open reading
frames [35]. Both mechanisms show striking variation
across tissue types, and therefore, it would not be possible
to attribute variations in PTC+ transcript levels in various
tissues to differences in NMD efficiency, as they could also
be due to differences in the levels of alternative splicing,
or in the use of alternative translation start sites.
NMD efficiency is sometimes calculated as the ratio
between the amount of mutant transcripts in the absence
and in the presence of a NMD inhibitor (often a transla-
tion inhibitor) [31,32,36], which would have the advan-
tage in the present case to bypass the aforementioned
problem. However, notwithstanding the fact that it is
impossible to inhibit NMD in non-growing cells, it is to
be noted that the level of up-regulation upon NMD inhi-
bition is highly variable among NMD-sensitive transcripts
and it has never been demonstrated that this level corre-
lates with NMD efficiency. On the contrary, the results we
obtained when studying BRCA1/2  transcripts bearing
truncating mutations showed that it is not the case [4,37].
It has been shown recently that RNPS1, a protein compo-
nent of the EJC, could determine the variability of NMD
efficiency in three strains of HeLa cells [29]. However, we
did not find in our study on Men1+/Δ mice a correlation
between NMD efficiency in tissues and the level of tran-
scripts encoding RNPS1, no more than with the levels of
the other transcripts that we have tested. It remains possi-
ble that these transcript levels are not reflective of the
amount of proteins present in these tissues.
Conclusion
The level of intertissue variations that we have found
might be lower than expected based on previous results
[14]. Nevertheless, if it were to reflect the situation in
humans, there may be circumstances where this two-fold
difference is sufficient to modify the ultimate phenotype
by allowing the expression of twice as many aberrant trun-
cated proteins with potential dominant-negative or gain-
of-function in particular tissues compared to others. Fur-
thermore, the observed variation means that the stability
of nonsense transcripts may significantly differ in the rel-
evant tissues from the stability determined in commonly
used cell lines.
Methods
Mice, cells and tissues
Heterozygous mice carrying the deleted Men1  allele
(Men1+/Δ) are from a mixed 129/Sv and C57BL/6 back-
ground [17]. Mouse embryonic fibroblasts (MEF) were
isolated from littermates of E12.5 embryos derived from
intercrosses of Men1+/Δ  mice [17] and immortalized
according to 3T3 protocol published previously [38]. Tis-
sues (stomach, liver, heart, spleen, lung, mammary gland,
kidney, ovary, testis, brain, intestine, thymus and adrenal)
were harvested from 4 two month-old Men1+/Δ mice (2
male and 2 female), briefly washed in phosphate-buffered
saline (PBS), quickly frozen in liquid nitrogen and trans-
ferred for long term storage at -80°C.
All animal experiments were conducted in accordance
with the standards of human animal care and were
approved by the International Agency for Research on
Cancer's Animal Care and Use Committee.
Cell culture
MEF cells were maintained in Dulbecco's modified Eagle
medium (Invitrogen, Cergy Pontoise, France) supple-
mented with 10% foetal calf serum, 100 units/ml penicil-
lin, 100 μg/ml streptomycin, 2 mM L-glutamine (VWR,
Fontenay sous Bois, France) and 100 μM β-mercaptoetha-
nol in a 5% CO2 incubator at 37°C.
For NMD (translation) inhibition, cells were treated with
a fresh puromycin solution (Sigma-Aldrich, St Quentin
Fallavier, France) at the final concentration of 100 μg/mlBMC Genetics 2008, 9:83 http://www.biomedcentral.com/1471-2156/9/83
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of culture for 6 hours and harvested, washed once with
PBS, and subsequently used for total RNA isolation.
RNA extraction and reverse transcription
Frozen tissues were homogenized in liquid nitrogen using
a CRYOPIX® grinder (Alphelys, Plaisir, France). Total RNA
was isolated from 5 × 106 MEF cells or from ~30 mg of tis-
sue powder using the NucleoSpin RNA II kit (Macherey-
Nagel, Hoerdt, France), according to the manufacturer's
instructions.
RNA concentrations were quantified with a Biophotome-
ter (Eppendorf, Le Pecq, France) and integrity of RNA was
checked by 1% agarose gel electrophoresis. Protein con-
tamination was monitored by A260/A280 ratio. All sam-
ples had a ratio between 1.7 and 2.
A constant amount of 500 ng of total RNA was reverse
transcribed in a total volume of 20 μl using 20 pmol of
oligo(dT) primers (Promega, Charbonnières, France) and
50 units of Expand Reverse Transcriptase (Roche, Meylan,
France) according to the manufacturer's instructions. All
tissues of each mouse were reverse transcribed at the same
time, and all investigated samples have been reverse tran-
scribed using the same batch of oligo(dT) and enzyme.
Real-time PCR
PCR amplification and analysis were achieved using a
LightCycler 2.0 instrument (Roche) and software version
4.0, respectively (Roche). The specific primers for quanti-
tative real-time PCR were designed using publicly availa-
ble sequences from the Nucleotide Sequence Database
(see Additional file 1). To amplify wild-type Men1 tran-
scripts, we used a forward primer complementary to a
sequence localised in exon 3 (absent in the mutant Men1
transcript species) and a reverse primer complementary to
a sequence localised at the exon 3/exon 4 junction. To
amplify mutant Men1  transcripts, we used a forward
primer complementary to a sequence localised in exon 2
and a reverse primer complementary to a sequence local-
ised at the exon 2/exon 4 junction. The primers designed
to amplify the transcripts of the genes encoding NMD fac-
tors, splicing factors, or the control genes also span at least
one exon-exon junction (except for Upf3b and Hprt1). All
primers were synthesized by MWG Biotech AG. Master-
mix for each PCR run was prepared in a total volume of 10
μl with 2.5 or 5 mM MgCl2 (see Additional file 2), 0.5 μM
of each primer, 1 μl LightCycler Fast Start DNA Master
SYBER Green I mix, and 2 μl of cDNA. All templates were
amplified using the following protocol: after 10 min of
denaturation at 95°C, samples were subjected to 40 cycles
of denaturation for 15 s at 95°C, annealing for 5 s at 64°C
or 66°C (see Additional file 1), and elongation for 10 s at
72°C. A melting curve was performed at the end of the 40
cycles by heating the samples at a rate of 0.2°C/s starting
at 70°C up to 97°C with continuous measurement of flu-
orescence. The specificity of the real time RT-PCR reaction
performed to amplify Men1  wild-type or mutant tran-
script species was controlled using RNA extracted from
Men1+/+ and Men1-/- MEF cells.
Each sample was analysed by at least three PCR reactions.
Absolute quantification of RNA copy number was deter-
mined using a standard curve that is generated with serial
dilutions of a PCR product with a known concentration
(as measured with the Biophotometer).
NMD efficiency and transcript levels assessment
NMD efficiency is expressed as the ratio of the number of
mutant versus wild-type Men1 RNA copies in each tissue.
To assess the level of expression of the 11 genes encoding
proteins involved in NMD and of the wild-type Men1
allele, in each of the 13 tissues, the number of RNA copies
was normalized with the average number of RNA copies
for the Hprt1 and β-actin genes. Copy numbers of the tran-
scripts of these two genes are shown in Additional file 1.
Statistical analysis
To test the significance of the differences between tissues,
transcript measurements being nested within tissue and
tissues being nested within mouse, data were modelled
using a hierarchical mixed model [39]. The "tissue" factor
was studied as a fixed effect and the "mouse" factor
embedded within the "tissue" factor as a random effect in
order to take into account the within-mouse correlation.
Estimations were done using the maximum likelihood
method using the nlme library of the software R version
2.2.1 [40]. The statistical significance level was 0.05.
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